Home >> CAP TODAY Recommends >> Cancer Biomarkers Conference III

Cancer Biomarkers Conference III

Print Friendly, PDF & Email

Houston Methodist Department of Pathology and Genomic Medicine is presenting its Cancer Biomarkers Conference III, Sept. 15–16, at the Houston Methodist Research Institute.

More than 20 speakers will cover topics such as updates on PD-L1 testing for lung cancer, urologic cancers, and melanoma, the current approach to using cytology specimens for biomarker testing, the oncologist’s approach to TKI therapy, and many more.

The conference’s educational objectives include distinguishing the proper collection, management, and submission of pathology specimens for cancer biomarker testing; stating the clinical rationale for patient selection and treatment based on cancer biomarkers; defining regulations and billing for molecular testing focused on cancer biomarker testing; and describing the most current biomarkers and testing guidelines for multiple solid cancers and hematologic cancers.

For further event details, go to events.houstonmethodist.org/cancerbiomarkers.


Check Also

Molecular ‘bucket list’ for renal cancer

September 2018—Leo Tolstoy is not listed as a coauthor on the most recent iteration of The Cancer Genome Atlas on renal cell carcinoma, which focuses on molecular characterization of RCC. But the topic is as rich and complex as a Russian novel, and the authors’ approach is so comprehensive, it’s tempting to picture them at least holding forth at a certain soirée in Saint Petersburg (minus the after-party drunkenness and the bit with a bear, of course). The project may not be as sprawling as War and Peace, which marches 559 characters, speaking two languages, over four volumes, 15 parts, and 333 chapters. It’s a heroic effort nonetheless. There is much to keep track of in renal cell carcinoma, both generally and in this latest document, which evaluates 843 RCCs from three major histologic subtypes, including 488 clear cell RCC, 274 papillary RCC, and 81 chromophobe RCC.